Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | EML4 - ALK |
Therapy | Crizotinib |
Indication/Tumor Type | clear cell renal cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
EML4 - ALK | clear cell renal cell carcinoma | sensitive | Crizotinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Xalkori (crizotinib) treatment inhibited tumor growth in a cell line xenograft model of clear cell renal cell carcinoma expressing EML4-ALK (PMID: 32020234). | 32020234 |
PubMed Id | Reference Title | Details |
---|---|---|
(32020234) | Identification of anaplastic lymphoma kinase fusions in clear cell renal cell carcinoma. | Full reference... |